Abstract | BACKGROUND AND AIMS: PATIENTS/METHODS: RESULTS:
PSA-NCAM expression was highest in patients with undifferentiated neuroblastoma and advanced stages of disease, whereas children with differentiated tumor types and low clinical stages had distinctly reduced or no reactivity in immunohistochemistry and, simultaneously, normal serum levels. PSA-NCAM expression correlated with other prognostic and diagnostic markers, such as MYCN gene amplification, and serum concentrations decreased during successful treatment. CONCLUSIONS: We conclude that PSA-NCAM, both immunohistochemically and in the serum, is a promising candidate for another useful diagnostic and prognostic tumor marker in childhood neuroblastoma.
|
Authors | S Glüer, M Zense, E Radtke, D von Schweinitz |
Journal | Langenbeck's archives of surgery
(Langenbecks Arch Surg)
Vol. 383
Issue 5
Pg. 340-4
(Oct 1998)
ISSN: 1435-2443 [Print] Germany |
PMID | 9860228
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Neural Cell Adhesion Molecule L1
- Neural Cell Adhesion Molecules
- Sialic Acids
- polysialyl neural cell adhesion molecule
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
(analysis)
- Biopsy, Needle
- Child
- Child, Preschool
- Female
- Ganglioneuroma
(blood, diagnosis, drug therapy)
- Humans
- Immunohistochemistry
- Infant
- Male
- Neoplasm Staging
- Neural Cell Adhesion Molecule L1
- Neural Cell Adhesion Molecules
(analysis, blood)
- Neuroblastoma
(blood, diagnosis, drug therapy)
- Peripheral Nervous System Neoplasms
(blood, diagnosis, drug therapy)
- Prognosis
- Sensitivity and Specificity
- Sialic Acids
(analysis, blood)
- Sympathetic Nervous System
- Treatment Outcome
|